| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0378-5122(02)00147-0 |
| P698 | PubMed publication ID | 12361887 |
| P2093 | author name string | Hermann P G Schneider | |
| P2860 | cites work | A genetic model for colorectal tumorigenesis | Q27860582 |
| Genetic instabilities in human cancers | Q28131826 | ||
| The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients | Q28235260 | ||
| Intratumoral levels of estrogens in breast cancer. | Q33695014 | ||
| Is estradiol a genotoxic mutagenic carcinogen? | Q33851357 | ||
| Incessant ovulation--a factor in ovarian neoplasia? | Q34051579 | ||
| Estrogen and the risk of breast cancer | Q34137105 | ||
| The selective estrogen enzyme modulator (SEEM) in breast cancer | Q34268848 | ||
| Hormone replacement therapy and breast cancer: a qualitative review | Q34351285 | ||
| Hormone replacement therapy and survival after surgery for ovarian cancer | Q35178365 | ||
| Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study | Q35707414 | ||
| Estrogen receptor-positive proliferating cells in the normal and precancerous breast. | Q35787982 | ||
| Hormone levels in older women: a study of post-menopausal breast cancer patients and healthy population controls | Q35981858 | ||
| Endometrial and ovarian cancer and oral contraceptives--findings in a large cohort study | Q36081029 | ||
| The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk | Q36465880 | ||
| Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk | Q36618233 | ||
| Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis | Q36700830 | ||
| 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. | Q37363103 | ||
| A prospective study of endogenous estrogens and breast cancer in postmenopausal women | Q39378468 | ||
| Controversial issues in the management of early epithelial ovarian cancer: conservative surgery and role of adjuvant therapy | Q40579743 | ||
| Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk | Q40862149 | ||
| Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction | Q41160138 | ||
| Estrogen replacement in surgical stage I and II endometrial cancer survivors | Q41243007 | ||
| Noncontraceptive estrogen use and epithelial ovarian cancer | Q41281883 | ||
| Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice | Q41400379 | ||
| Breast cancer and the role of cytokines in regulating estrogen synthesis: an emerging hypothesis | Q41613405 | ||
| A case-control study of oral contraceptive use and invasive epithelial ovarian cancer | Q43487660 | ||
| Involvement of up-regulation of 17?-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers | Q43824457 | ||
| Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women | Q44415988 | ||
| Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group | Q46309970 | ||
| Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group | Q47701078 | ||
| Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women | Q50672431 | ||
| Steroid sulfatase activities in human breast tumors | Q54276307 | ||
| Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies | Q57560922 | ||
| Tissue androgens and the endocrine autonomy of breast cancer | Q63359292 | ||
| A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer | Q64130667 | ||
| Gas chromatography/mass spectrometry of catechol estrogens | Q67507533 | ||
| Nature of cytochromes P450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes | Q67591984 | ||
| Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group | Q67979093 | ||
| Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group | Q67979095 | ||
| Administration of estrogens to patients with a previous diagnosis of endometrial adenocarcinoma | Q68464401 | ||
| Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women | Q68590210 | ||
| Monooxygenase mediating catecholestrogen formation by rat anterior pituitary is an estrogen-4-hydroxylase | Q69326021 | ||
| Prevention of endometrial cancer with progestogens | Q69597792 | ||
| In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostenedione | Q69679047 | ||
| Aromatase activity in primary and metastatic human breast cancer | Q69716761 | ||
| Endometrial adenocarcinoma in stein-leventhal syndrome | Q69812605 | ||
| Proposal to decrease the risk and improve the prognosis of breast cancer | Q70607072 | ||
| The conversion of androstenedione to estrone, estradiol, and testosterone in breast tissue | Q71217828 | ||
| Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Survey of Women's Health Study Group | Q71740564 | ||
| Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions | Q74136965 | ||
| PRECURSORS OF CORPUS CANCER. IV. ADENOMATOUS HYPERPLASIA AS STAGE O CARCINOMA OF THE ENDOMETRIUM | Q76590515 | ||
| Postmenopausal estrogen-progestin therapy and breast cancer: a clinical response to epidemiological reports | Q77811543 | ||
| Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. The Esclim Study Group | Q78016942 | ||
| P921 | main subject | Hormone Replacement Therapy | Q108667313 |
| P304 | page(s) | S35-52 | |
| P577 | publication date | 2002-08-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Maturitas | Q15766577 |
| P1476 | title | HRT and cancer risks | |
| P478 | volume | 43 Suppl 1 |
| Q24805637 | Estrogen, progesterone and epithelial ovarian cancer |
| Q64379477 | Mutual Contribution of Pten and Estrogen to Endometrial Carcinogenesis in a PtenloxP/loxP Mouse Model |
| Q33703792 | Novel hydroxysteroid (17beta) dehydrogenase 1 inhibitors reverse estrogen-induced endometrial hyperplasia in transgenic mice |
| Q37798330 | Steroid hormone receptors in cancer development: A target for cancer therapeutics |
Search more.